Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
| | | |

Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19

On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveï¾™ (casirivimab and…